Guy L.
- Country
- France
- Department
- Hématologie et oncologie pédiatrique
Research Overview
- Interfant-21: International collaborative treatment protocol for infants under one year with KMT2A-rearranged acute lymphoblastic leukemia or mixed phenotype acute leukemia
- International Pediatric Study of Arsenic Trioxide and Tretinoin ± Gemtuzumab Ozogamicin for Acute Promyelocytic Leukemia in Children and Adolescents
- Phase III Randomized Trial of Gemtuzumab Ozogamicin with Induction Chemotherapy in Pediatric Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, and Myeloid Sarcoma
Data & Insights
Has run more than one trial at 49 of 160 partner sites.
Specializations
Pediatric Hematologic Oncology
This investigator specializes in treating complex blood cancers in children, with particular focus on acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). Their expertise extends to managing rare conditions like high-risk myelodysplastic syndrome and isolated myeloid sarcoma.
- Infant Leukemia Treatment
- KMT2A-rearranged ALL
- Advanced Chemotherapy Protocols
Therapeutic Innovation
The investigator explores innovative treatment combinations involving gemtuzumab ozogamicin with traditional chemotherapy agents. Their work includes evaluating different therapeutic approaches using cytarabine, mitoxantrone, and liposomal daunorubicin.
- Combined Therapy Approaches
- Targeted Immunotherapy
- Dose Optimization Studies
Stem Cell Transplantation
The investigator studies various conditioning regimens for hematopoietic stem cell transplantation, comparing myeloablative conditioning approaches with reduced intensity conditioning protocols.
- Transplant Conditioning Protocols
- Post-transplant Outcomes
- Risk-adapted Treatment Strategies
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.